ABSTRACT

The extensive use of angiotensin-converting enzyme inhibitors (ACEIs) as antihypertensive agents and the huge amount of data collected in clinical trials and post-marketing studies has allowed the extending of the indication of ACEIs beyond blood pressure control. Current guidelines recommend ACEIs in symptomatic patients with heart failure with reduced ejection fraction to decrease the risk of heart failure hospitalization, and also in patients after acute myocardial infarction (AMI) with ST-elevation with or without post-AMI ventricular dysfunction. Analyzing the association between the choice of an ACEI after AMI with the risk of mortality and re-infarction, a class effect, rather than the superiority of some agents, has been described. The focus of this review is centered on the role of ACEIs in addition to and beyond blood pressure control. It summarizes clinical evidence on the use of these agents in cardiovascular diseases, with a specific interest in the experience with zofenopril, which presents a peculiar pharmacological profile that may contribute to additional clinical benefits in some identifiable populations of patients. Indeed, the presence of a sulfhydryl group in its structure confers on zofenopril high anti-oxidant and anti-ischemic properties involving the activation of the H2S system, resulting in a cardioprotective effect. The efficacy and safety of zofenopril have been extensively evaluated and proved in the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) program in numerous clinical settings. The pharmacological features and ancillary characteristics of zofenopril with potent cardioprotective effects seem to differentiate it from other ACEIs and to confer further benefits to patients.

Keywords: ACE inhibitor; Bradykinin; Myocardial infarction; SMILE study; Sulfhydryl group; Zofenopril
**Key Summary Points**

Angiotensin-converting enzyme inhibitors (ACEIs) are currently recommended for managing arterial hypertension, the progression of chronic renal disease, post-myocardial infarction, congestive heart failure, and type 2 diabetes mellitus.

In patients with acute or chronic coronary syndrome and heart failure ACEIs appear to provide several benefits beyond blood pressure control.

Among the various drugs of this class, zofenopril, a lipophilic, sulfhydryl group-containing ACEI, seems to contribute to additional clinical benefits in some identifiable populations of subjects.

The clinical efficacy and safety of zofenopril has been evaluated in more than 3,600 post-acute myocardial infarction patients with or without left ventricular dysfunction in the four randomized controlled trials of the SMILE program.

The pharmacological characteristics and ancillary features of zofenopril with potent cardioprotective activity seem to differentiate it from other ACEIs and to confer further benefits to patients.

**INTRODUCTION**

Given the consolidated clinical experience in the use of therapies blocking the renin-angiotensin system (RAS), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II-receptor blockers (ARBs) have become a first-line strategy for managing arterial hypertension, the progression of chronic renal disease, post-myocardial infarction, congestive heart failure, and type 2 diabetes mellitus [1, 2]. These results have been generated by a large number of randomized clinical trials and observational post-surveillance studies that have demonstrated the clinical efficacy of RAS blockade in daily practice and in patients with presumed RAS activation and without hypertension [2]. The focus of this review is centered on the role of ACEIs beyond blood pressure (BP) control and summarizes the clinical evidence on the use of these agents in patients with different settings of cardiovascular diseases (CVDs). Specific attention is paid to the experience with zofenopril because of its peculiar pharmacological properties, mainly related to the sulfhydryl group present in its molecular structure. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

**RAS INVOLVEMENT IN CVD**

The RAS is one of the main physiological systems responsible for homeostatic control of arterial pressure, electrolyte balance, organ perfusion, and extracellular volume. Its modulation has several important effects that mainly involve CVDs and renal disease [3]. The pathway is initiated by renin which cleaves the N-terminal portion of angiotensinogen to form the biologically inactive decapeptide angiotensin I [4]; this inactive peptide is then hydrolyzed by ACE which removes the C-terminal dipeptide in order to form the octapeptide angiotensin II, biologically active as a vasoconstrictor [4]. Angiotensin II is the primary effector of a variety of RAS-induced physiological and pathophysiological actions. It interacts with 4 receptor subtypes expressed in the CV system (vasoconstriction, increased BP, increased cardiac contractility, vascular and cardiac hypertrophy), kidney (renal tubular sodium reabsorption, inhibition of renin release), sympathetic nervous system, and adrenal cortex (stimulation of aldosterone synthesis), as well as in the lung and the gut where it plays a remarkable role in fluid balance and respiratory function [5, 6].

Therefore, a dysregulation of RAS is reported not only in essential hypertension and in the
response of CV and renal tissue to hypertensive and non-hypertensive injury but also in many other CV disorders [4]. Angiotensin II is involved in the development of both vascular and cardiac hypertrophy and remodeling, vascular damage, renal damage, and atherosclerosis with a mechanism that is only partially dependent on elevated BP values. [4]. In congestive heart failure (HF), the reduced cardiac function and the renal under-perfusion related to a reduced effective intravascular volume are responsible for renin hypersecretion and secondary aldosteronism, contributing to pulmonary congestion and development of edema. In these patients, angiotensin II increases peripheral vascular resistance (cardiac afterload) and enhances progressive ventricular dysfunction contributing to the progression of heart failure [4].

ACEI and ARB medications both target RAS, and are recommended in the treatment of several types of CVD (Fig. 1). However, the optimal choice between these two groups of medications for the prevention of CVD is not well established [3].

ACEIs prevent the conversion of angiotensin I to angiotensin II by competing with angiotensin I for the active site of ACE. The reduction of angiotensin II formation decreases vasoconstriction and aldosterone secretion and increases plasma renin. As a consequence, ACEIs can lower BP, total peripheral resistance, and sodium and water retention [7]. ACEIs also reduce both preload and afterload through arterial and venous dilation. These hemodynamic effects are particularly beneficial in the presence of left ventricular dysfunction (LVD) [8]. One disadvantage of ACEIs is that the presence of non-ACE pathways results in continued low-level production of angiotensin II, despite the inhibition of ACE. ARBs are selective ligands of AT1 receptors; these drugs achieve their clinical goals bypassing the limitations of ACE escape phenomena and non-ACE sources of angiotensin II formation, despite the increased blood angiotensin II levels due to blockade of AT1-mediated receptor internalization (Fig. 1) [3, 9].

Fig. 1 Renin-angiotensin system and related molecules. Many molecules influence the effects of renin-angiotensin system activation. Angiotensin II and AT1R are key molecules of the major harmful pathway in the cardiovascular system. Counteracting pathways with cardiovascular protective property also exist. There are controversies about the effects of AT2R signaling, which are indicated in gray italic [3]. ARB angiotensin receptor blocker, AT1R angiotensin type one receptor, AT2R angiotensin type two receptor, AT3R angiotensin type three receptor, AT4R angiotensin type four receptor, CAGE chymostatin-sensitive angiotensin-II-generating enzyme, MasR Mas receptor, MMP-8 matrix metalloproteinase-8, NEP neutral endopeptidase, PCP prolyl carboxypeptidase, PEP prolyl endopeptidase, RAS renin-angiotensin system, VSMC vascular smooth muscle cell

ROLE OF ACEIS IN CVD ACCORDING TO CURRENT GUIDELINES

ACEIs are widely prescribed to manage hypertension, and are recommended in recent guidelines (level of recommendation IA) as the basis of antihypertensive strategies, given their ability to reduce BP and CV events in randomized clinical trials [10]. The potency of ACE inhibition is influenced by the affinity of the drug to the zinc (Zn++) ligand of ACE. There are three distinct chemical classes of ACEIs (Table 1): (1) sulphydryl containing ACEIs (i.e., captopril, zofenopril) which strongly bind the Zn++ ligand, but disulfide formation limits their half-life; (2) drugs containing a carboxyl...
| Drug     | Molecular structure | Absorption (%) | Half-life (h) | Metabolism | Main route of elimination | Approved indications            | Hypertension | Heart failure |
|----------|---------------------|----------------|---------------|------------|--------------------------|---------------------------------|--------------|--------------|
|          |                     |                |               |            |                          |                                 | Initial      | Initial       | Maximal      | Initial      | Initial       |
|          |                     |                |               |            |                          |                                 | daily dose   | daily dose   | daily dose   | daily dose   | daily dose   |
| Benazepril | Dicarboxylic group | 37             | 10–11         | + (benazeprilat) | Renal         | Hypertension                  | 10           | 40           | –            | –            |
| Captopril | Sulphhydryl group   | 60–75          | 2             | +           | Renal         | Hypertension, heart failure, post-AMI patients with LVD, type 1 diabetic nephropathy | 12.5 (tid)    | 150 (tid)    | 6.25 (tid)   | 150 (tid)    |
| Cilazapril | Dicarboxylic group | 45–85          | 1.5–2.0       | + (cilazaprilat) | Renal         | Hypertension and heart failure | 1–1.25       | 5            | 0.5          | 5            |
| Enalapril | Dicarboxylic group  | 60             | 11–14         | + (enalaprilat) | Renal         | Hypertension and heart failure (or asymptomatic LVD) | 5            | 40           | 2.5          | 20 (bid)     |
| Fosinopril | Phosphonate group   | 36             | 12            | + (fosinoprilat) | Renal and hepatic | Hypertension and heart failure | 10           | 40           | 5–10         | 40           |
| Lisinopril | Dicarboxylic group  | 25             | 12            | –           | Renal         | Hypertension, heart failure and post-AMI hemodynamically stable patients | 10           | 40           | 2.5–5        | 40           |
| Moexipril | Dicarboxylic group  | 13             | 2–9           | + (moexiprilat) | Renal         | Hypertension                  | 7.5          | 30           | –            | –            |
| Perindopril | Dicarboxylic group | 65–75          | 1.2           | + (perindoprilat) | Renal         | Hypertension and stable CAD patients | 4            | 16           | –            | –            |
| Quinapril | Dicarboxylic group  | 50–80          | 2.3           | + (quinaprilat) | Renal         | Hypertension and heart failure | 10–20        | 80           | 5 (bid)      | 20 (bid)     |
| Drug          | Molecular structure | Absorption (%) | Half-life (h) | Metabolism Main route of elimination | Approved indications                      | Hypertension | Heart failure |
|--------------|---------------------|----------------|--------------|--------------------------------------|------------------------------------------|--------------|---------------|
|              |                     |                |              |                                      |                                           |             | Initial daily dose (mg) | Maximal daily dose (mg) | Initial daily dose (mg) | Initial daily dose (mg) |
| Ramipril     | Dicarboxylic group  | 50–60          | 13–17        | + (ramiprilat) Renal                 | Hypertension, heart failure (post-AMI), high risk CV patients | 2.5          | 20            | 2.5              | 5 (bid)                |
| Trandolapril | Dicarboxylic group  | 40–60          | 16–24        | + (trandolaprilat) Hepatic           | Hypertension and post-AMI (CHF or asymptomatic LVD patients) | 1–2          | 4             | 1                | 4                      |
| Zofenopril   | Sulfhydryl group    | 78             | 5.5          | + (zofenoprilat) Renal               | Hypertension and post-AMI (< 24-h)       | 15           | 60            | –                | –                      |

| Drug         | Post-AMI Other indication | Maximal daily dose (mg) | Maximal daily dose (mg) |
|--------------|----------------------------|-------------------------|-------------------------|
| Benazepril   | –                          | –                       | –                       |
| Captopril    | 6.25 (tid)                 | 50 (tid)                | –                       |
| Cilazapril   | –                          | –                       | –                       |
| Enalapril    | –                          | –                       | –                       |
| Fosinopril   | –                          | –                       | –                       |
| Lisinopril   | 5                          | 10                      | –                       |
| Moexipril    | –                          | –                       | –                       |
| Perindopril  | –                          | –                       | 4                       | 8                                     |
| Quinapril    | –                          | –                       | –                       | –                                     |
| Ramipril     | –                          | –                       | 2.5                     | 10                                    |
| Trandolapril | 1                          | 4                       | –                       | –                                     |
group (i.e., enalapril, lisinopril, ramipril) that binds to side chains of the enzyme within the active moiety for improved potency and duration of action; and (3) drugs composed of phosphorus-containing ACEIs (i.e., fosinopril) [11, 12]. Although direct ACEIs comparisons among available agents are rare, a Cochrane review has demonstrated that there are no clinically meaningful differences in BP-lowering efficacy between different ACEIs [13].

ACEIs are the mainstay not only for hypertension management but also for other CVD, including HF, LVD, and acute myocardial infarction (AMI) (Table 2). In HF, ACEIs decrease total peripheral resistance, pulmonary vascular resistance, pulmonary capillary wedge pressure, and mean arterial and right atrial pressures, thus resulting in reduced mortality, regardless of HF severity [7, 8]. In these patients, the use of ACEIs has been shown to increase cardiac index, cardiac output, stroke volume, and exercise tolerance [7]. Many pieces of evidence indicate that BP control delays the onset of HF and, in some cases, contributes to prolonging life, and this also applies to hypertensive patients treated with ACEIs with or without a history of myocardial infarction, especially in older people [14]. As per current guidelines, an ACEI is recommended in addition to a beta-blocker for symptomatic patients with HF with reduced left ventricular ejection fraction (LVEF) to reduce the risk of HF hospitalization and death (recommendation 1A) [15]. A meta-analysis of three randomized trials (SAVE, Survival and Ventricular Enlargement; AIRE, Acute Infarction Ramipril Efficacy; and TRACE, trandolapril in patients with reduced LVD after acute myocardial infarction), including 5966 patients with LVD or HF, have indicated that administration of ACEIs after AMI provides clear benefit and lead to substantial reductions in mortality and morbidity in high-risk patients [16]. Indeed, the proportion of patients readmitted for HF resulted was reduced by 27% with ACEIs [11.9% in the ACEI group vs. 15.5% of the control group; hazard ratio (HR) 0.73 95% CI 0.63–0.85, \( p < 0.0001 \)], while the combination of death or hospital admission for HF occurred in 30.5% of the ACEI group and 37.0% of the control group [17].

| Drug     | Post-AMI Other indication | Initial daily dose (mg) | Maximal daily dose (mg) |
|----------|---------------------------|------------------------|------------------------|
| Zofenopril | AMI acute myocardial infarction, CAD coronary artery disease, CHF congestive heart failure, LVD left ventricular dysfunction, LID left ventricular dysfunction | 7.5 [bid] | 30 [bid] |
|          | bid twice-a-day tid three-times-a-day | | |

Table 1 continued
Table 2  Current recommendations of the European Society of Cardiology for the use of angiotensin converting enzyme inhibitors in patient with cardiovascular disease

| Recommendations for treating arterial hypertension [10] | Class of recommendation | Level of evidence |
|---------------------------------------------------------|--------------------------|------------------|
| Among all antihypertensive drugs, ACEIs, ARBs, BBs, CCBs, and diuretics (thiazides and thiazide-like drugs such as chlorthalidone and indapamide) have demonstrated effective reduction of BP and CV events in RCTs, and are thus indicated as the basis of antihypertensive treatment strategies | I | A |
| Combination treatment is recommended for most hypertensive patients as initial therapy. Preferred combinations should comprise a RAS blocker (either an ACEI or an ARB) with a CCB or diuretic. Other combinations of the five major classes can be used | I | A |
| It is recommended that if BP is not controlled with a two-drug combination, treatment should be increased to a three-drug combination, usually a RAS blocker with a CCB and a thiazide/thiazide-like diuretic, preferably as an SPC | I | A |

| Recommendations for treating patients with symptomatic HF with reduced ejection fraction [15] | Class of recommendation | Level of evidence |
|---------------------------------------------------------------------------------|--------------------------|------------------|
| An ACEI is recommended, in addition to a BB, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death | I | A |
| A BB is recommended, in addition to an ACEI, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death | I | A |
| An MRA is recommended for patients with HFrEF who remain symptomatic despite treatment with an ACEI and a BB to reduce the risk of HF hospitalization and death | I | A |

| Recommendations for treating chronic coronary syndrome [18] | Class of recommendation | Level of evidence |
|-------------------------------------------------------------|--------------------------|------------------|
| ACEIs (or ARBs) are recommended if a patient has other conditions (e.g., HF, hypertension, or diabetes) | I | A |
| ACEIs should be considered in CCS patients at very high risk of CV events | IIa | A |

| Recommendations for treating STEMI [22] | Class of recommendation | Level of evidence |
|----------------------------------------|--------------------------|------------------|
| ACEIs are recommended, starting within the first 24-h of STEMI in patients with evidence of HF, LVSD, diabetes, or anterior AMI | I | A |
| An ARB, preferably valsartan, is an alternative to ACEIs in patients with HF and/or LVSD, particularly those who are intolerant to ACEIs | I | B |
| ACEIs should be considered in all patients in the absence of contraindications | IIa | A |

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BP blood pressure, BB beta-blocker, CCB calcium channel blocker, CCS chronic coronary syndrome, CV cardiovascular, HF heart failure, HFrEF heart failure with reduced ejection fraction, LVSD left ventricular systolic dysfunction, MRA mineralocorticoid receptor antagonist, RAS renin-angiotensin system, RCT randomized controlled trial, SPC single-pill combination, STEMI ST-segment elevation myocardial infarction

△ Adis
indicated in patients with asymptomatic LV systolic dysfunction in order to minimize the risk of development of HF, and consequent hospitalization, and death [15].

In patients affected by coronary artery disease (CAD) with preserved systolic ventricular function, the evidence for routine administration has been conflicting. A metaanalysis by Al-Mallah et al. reported a modest benefit of ACEIs on the prognosis of patients with CAD associated with preserved LV systolic function [17]. Data from more than 33,000 patients indicated that ACEIs therapy, when added to conventional therapy (aspirin, beta-blockers, and statins), was associated with a decrease in the rate of CV mortality (risk reduction or RR 0.83, 95% CI 0.72–0.96, p = 0.01), nonfatal MI (RR 0.84, 95% CI 0.75–0.94, p = 0.003), all-cause mortality (RR 0.87, 95% CI 0.81–0.94, p = 0.0003), and coronary revascularization (RR 0.93, 95% CI 0.87–1.00, p = 0.04) [17]. Not all trials, however, described an effective advantage in the use of ACEIs in this setting; hence, current guidelines generally do not recommend ACEIs in chronic coronary syndrome patients without HF or high CV risk, unless with coexisting hypertension, LVEF < 40%, diabetes, or chronic kidney disease. In these latter cases, ACEIs should be considered (level of recommendation IIA) [18].

Therapy with ACEIs is also common after AMI. Numerous trials have indicated that mortality and morbidity were reduced when ACEIs were administered in a relatively unselected population of patients in the acute phase of MI (“early”) or in patients with evidence of LVD in the subacute phase after MI (“late”) [19]. In their metaanalysis, Franzosi et al. collected data from large randomized trials which evaluated the efficacy and safety of treatments with ACEIs given in the acute phase of MI (0–36 h from the onset of symptoms) and continued for a short period of follow-up (generally 4–6 weeks) [20]. These trials were CONSENSUS-II, GISSI-3, ISIS-3, and CCS-1, and included a total of 98,496 patients. The main conclusions of the analysis were: (1) ACEI treatment can be started immediately during the acute phase of MI, in association with other routinely recommended treatments (such as thrombolytics, aspirin, and beta-blockers); (2) the benefit occurs during the first few days after MI, suggesting a positive role of tissue remodeling; (3) the benefit is proportionally larger in higher-risk subgroups (those with an anterior site MI or high heart rate); and (4) early benefits would be complementary to that observed later in trials of prolonged ACEI therapy initiated several days or weeks after MI in patients with evidence of HF or LVD [20]. Due to the lack of clinical trials that directly compared the efficacy of different ACEIs treatment after AMI, these drugs are generally assumed to be equally effective [21].

Analizing the association between the choice of an ACEI after MI with the risk for mortality and reinfarction, a class effect was described rather than a superiority of some agents, when drugs were used in comparable dosages, thus suggesting that it would be more important initiating treatment and continuing treatment at the recommended dosage than choosing a particular agent to achieve long-term benefits [21]. Current guidelines recommend ACEIs after AMI with ST-elevation, starting within the first 24 h of ST-elevation myocardial infarction (STEMI) in patients with evidence of heart failure, LV systolic dysfunction, diabetes, or an anterior infarct (level of recommendation IA). They should be considered in all patients with AMI unless specifically contraindicated (level of recommendation IIA) [22].

ACEIs are commonly used in patients with diabetes and/or with renal disease. In a systematic review including 36,917 participants (including 2400 deceased, 766 patients who required dialysis, and 1099 patients in which serum creatinine levels doubled), ACEIs showed higher probabilities of reducing all-cause mortality, use of dialysis, or doubling of serum creatinine levels, and demonstrated renoprotective effects [23]. These observations were confirmed even in chronic renal disease progression when ACEIs decreased BP, and urinary protein excretion slowed the increase in serum creatinine and reduced the risk for end-stage renal disease (ESRD), or for the combined outcome of doubling of the baseline serum creatinine concentration or ESRD by approximately 30% [24].
ZOFENOPRIL: A CARDIOPROTECTIVE ACEI

Zofenopril is a sulfhydryl ACEI featuring a high lipophilicity, long-lasting tissue penetration, selective cardiac ACEI, potent anti-oxidant activities, and good efficacy after a single daily administration (Table 3) [25]. Starting from 1990, its efficacy and safety have been evaluated in the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) project, a large clinical program aimed at investigating the role of zofenopril in the treatment of AMI in several populations of patients to test the hypothesis that its unique pharmacological profile could provide some benefits beyond ACE inhibition, in terms of CV event prevention (Table 4). The first trial was a pilot study that evaluated the safety of zofenopril administration within 24 h of the onset of AMI symptoms and provided some preliminary data of efficacy in terms of combined occurrence of death, non-fatal CV events, and severe adverse events after a 12-month follow-up [26]. A large clinical trial was then designed to determine the efficacy of 6-week zofenopril administration (15–60 mg twice daily) versus placebo in 1556 patients with MI not receiving thrombolysis and treated within 24 h of the onset of symptoms (SMILE-1). The incidence of death or severe congestive HF at 6 weeks (primary end-point) was significantly reduced in the zofenopril group, with risk reduction by 34% (95% CI 8–54%; p = 0.018). These positive outcomes were maintained after 1 year, observing a risk reduction for death of 29% (95% CI 6–51%; p = 0.011) [27]. Given the large size of population involved in the SMILE trials, many statistically pre-specified and adequately powered post hoc analyses on specific subgroups could be performed, providing evidence on zofenopril effects in older patients, and in patients with arterial hypertension [28], diabetes [29], hypercholesterolemia [30], metabolic syndrome [31], angina, or previous myocardial infarction or NSTEMI [32]. Zofenopril was then directly compared with two ACEIs in randomized clinical trials carried out in patients with coronary artery disease. In the SMILE-2 study, zofenopril was compared to lisinopril in 1024 patients with acute MI undergoing thrombolysis [33], while in the SMILE-4 study, the main comparison was between zofenopril and ramipril in combination with acetylsalicylic acid (ASA) in patients with post-MI left ventricular dysfunction. In the SMILE 2 trial, zofenopril slightly reduced the incidence of severe hypotension versus lisinopril (10.9% vs. 11.7%, p = 0.38), with a significant decrease in the rate of drug-related severe hypotension (6.7% vs. 9.8%, p = 0.048) without a difference in mortality or major CV complications [33]. SMILE-4 investigated whether the benefits of zofenopril or ramipril could be affected by a concomitant ASA administration in patients with LV dysfunction after AMI [34]. The occurrence of death or hospitalization for CV cause was significantly reduced with zofenopril (odds ratio: 0.70; 95% CI: 0.51–0.96; 4076 Adv Ther (2020) 37:4068–4085

| Pharmacological properties | Clinical effects |
|----------------------------|-----------------|
| Higher lipophilicity and tissue penetration | Effective prevention of CV events |
| Higher affinity and more persistent binding to tissue ACE (cardiac, renal and vascular) | Effective prevention of CV events |
| Lesser BK-dependent effect | Good safety (reduced frequency of hypotension, cough, and renal function deterioration) |
| Significant antioxidant effect | Significant anti-ischemic effect |
| Increased release and availability of H2S | Improved CV function |

ACE angiotensin-converting enzyme, BK bradikinin, CV cardiovascular
Table 4  Summary of main characteristics and outcomes of the SMILE Studies

| Study  | Period of the enrolment | Inclusion criteria                                                                 | Intervention (n) | Control (n) | Daily zofenopril dose | Control Treatment | Treatment duration (weeks) | Post treatment follow-up (weeks) |
|--------|-------------------------|-------------------------------------------------------------------------------------|-----------------|-------------|------------------------|-------------------|-----------------------------|----------------------------------|
| SMILE Pilot | 1988–1989              | AMI with lack of indication for a thrombolytic therapy                              | 101             | 103         | 15–30 mg               | Placebo           | 48                          | –                                |
| SMILE-1 | 1991–1992              | Anterior AMI not eligible for thrombolytic therapy in the previous 12 h             | 772             | 784         | 15–60 mg               | Placebo           | 6                           | 48                               |
| SMILE-2 | 1998–1999              | Thrombolytic treatment within 12 h from AMI and SBP > 100 mmHg                     | 504             | 520         | 15–60 mg               | Lisinopril 2.5–10 mg daily | 6                           | –                                |
| SMILE-3 | 1998–2001              | AMI in the preceding 6 weeks with preserved left ventricular ejection fraction (> 40%), prior thrombolysis and treatment with ACEIs | 172             | 177         | 15–60 mg               | Placebo           | 24                          | –                                |
| SMILE-4 | 2005–2009              | AMI in the previous 24 h treated or untreated with PTCA, with clinical and/or echocardiographic evidence of left ventricular dysfunction | 365             | 351         | 15–60 mg plus ASA100 mg daily | Ramipril 10 mg daily plus ASA100 mg daily | 48                          | –                                |
| SMILE Overall | 1991–2009        | The same of the SMILE-1 to -4 study                                               | 1808            | 1822        | 30–60 mg               | Placebo, lisinopril or ramipril | 6–48                        | –                                |

| Study       | Primary end-point         | Main results                                          | Subgroups analysis |
|-------------|--------------------------|-------------------------------------------------------|--------------------|
| SMILE Pilot | Safety of treatment      | Good tolerability of zofenopril                       | –                  |
|             |                          | Similar CV mortality to placebo                       |                    |
|             |                          | Reduced hospitalization                               |                    |
|             |                          | Improved LVEF                                         |                    |
| Study   | Primary end-point                                                                 | Main results                                                                 | Subgroups analysis                                                                                                                                 |
|---------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| SMILE-1 | Occurrence of death or severe congestive heart failure over 6 weeks              | Improved short-term (6-weeks) and long-term (1-year) outcome                  | Superior efficacy of zofenopril compared to placebo, also in subjects with diabetes, hypercholesterolemia, metabolic syndrome, hypertension and NSTEMI |
| SMILE-2 | Occurrence of severe hypotension (SBP < 90 mmHg) at any time                     | Lower rate of severe hypotension with zofenopril compared to lisinopril      |                                                                                                                                                    |
| SMILE-3 | Global ischemic burden (ischemia on 24-h ambulatory ECG, ischemia or angina during treadmill test, recurrent AMI, need for revascularization) | Zofenopril significantly reduced the frequency and severity of exertional and spontaneous cardiac ischemia | Zofenopril significantly reduced the frequency and severity of exertional and spontaneous cardiac ischemia                                                                                            |
| SMILE-4 | Occurrence of CV mortality or hospitalization for CV causes                      | Efficacy of zofenopril associated with ASA superior to that of ramipril plus ASA | Superior efficacy of zofenopril compared to ramipril, also in subjects with diabetes, hypercholesterolemia, metabolic syndrome, hypertension and NSTEMI |
| SMILE Overall | 1-year combined occurrence of death or hospitalization for CV causes | Occurrence of CV events was significantly reduced with zofenopril vs. placebo and vs. the other ACEIs | Efficacy superior to placebo and ramipril, but similar to lisinopril in metabolic syndrome Non-significant trend for superiority of zofenopril vs. other ACEIs in hyperuricemic patients Zofenopril superior to placebo and the other ACEIs in hypertensive subjects and in those with at least one previous CV risk factor |
and this benefit was maintained during 5-year follow-up (Fig. 2) [34, 35]. The same results have been confirmed after a propensity analysis of the population and comparing subpopulations of patients appropriately matched for the main prognostic variables [36]. Finally, the cardioprotective effects of zofenopril were investigated in the SMILE-3 ISCHEMIA trial in 349 patients with preserved LV function after MI. In these patients receiving recommended standard treatment, zofenopril reduced the global burden of myocardial ischemia by decreasing the occurrence of significant ST-T abnormalities on ambulatory electrocardiography (ECG), ECG abnormalities or symptoms of angina during the standard exercise test, MI recurrence and the need for revascularization procedures, in comparison to placebo (20.3% vs. 35.9%, \( p = 0.01 \)) (Fig. 3) [37]. The results were not affected by demography, BP control, and concomitant pharmacological treatment, and supported some primary cardioprotective effect of zofenopril. More recently, the results of the SMILE-ischemia study were corroborated by a post hoc analysis of SMILE 4, stratifying patients by LVEF measured at baseline, and showing a reduction in 1 year and long-term mortality and hospitalization in post-MI with preserved LV function (Fig. 4) [38]. The cardioprotective properties of zofenopril were confirmed in a pooled analysis of the four SMILE studies [39] (Fig. 5).

THE RATIONALE OF THE CARDIOPROTECTIVE PROPERTIES OF ZOFENOPRIL

Zofenopril-mediated cardioprotection during ischemia/reperfusion seems to be associated with an increased H\(_2\)S and nitric oxide (NO) signaling. Hydrogen sulfide is a cytoprotective physiological signaling molecule acting in concert with NO and carbon monoxide in order to maintain physiological homeostasis in both the heart and circulation. Experimental evidence indicates that H\(_2\)S donors, such as zofenopril, can attenuate the pathological consequences of myocardial ischemia/reperfusion injury and HF, reducing oxidative stress and inflammation and inhibiting apoptosis [40]. In experimental models, indeed, zofenopril preconditioning enhanced tissue antioxidant defense, thus preventing reactive oxygen species formation, following an ischemic injury during reperfusion. Furthermore, treatment with zofenopril upregulated the expression of antioxidant enzymes, such as Trx-1, GPx-1, and SOD-1, suggesting an enhancement in antioxidant defenses before ischemia that mitigate myocardial reperfusion injury [41]. As summarized in Fig. 6, the enhanced H\(_2\)S signaling, alongside the inhibition of angiotensin II formation and bradykinin metabolism, could represent a further explanation of additional beneficial effects provided by zofenopril [40]. In addition, ex vivo animal studies indicated that, at the heart level, where ACE inhibition may prevent ischemic damage, zofenopril produced a more striking and long-lasting ACE inhibition than ramipril and enalapril, and, to a lesser extent, than captopril and fosinopril; 60% of ACE inhibition could persist in the heart at least 8 h after administration, while it was much lower with other ACEIs [41]. Conversely, in the lung, zofenopril showed a lower potency in both inhibiting ACE and reducing bradykinin metabolism [41]; bradykinin accumulation in the airways with zofenopril is lower than that observed with other ACEIs, and this may partially explain the relatively low risk of coughing observed with zofenopril (Fig. 7) [42]. Indeed, a meta-analysis including hypertensive and post-myocardial infarction patients indicated that zofenopril-induced cough was generally of a mild to moderate intensity, occurred significantly (\( p = 0.001 \)) more frequently in the first 3–6 months of treatment (3.0% vs. 0.2% 9–12 months), and always resolved or improved upon therapy discontinuation [39].

CONCLUSIONS

The pharmacological features of zofenopril provide cardioprotective, anti-ischemic, and anti-oxidant effects that differentiate it from other ACEIs. Zofenopril was evaluated as an early treatment after AMI, showing both short- and long-term benefits, and it has been
confirmed as a feasible and effective therapy in many subgroups of patients with CV and metabolic comorbidities. Therefore, as well as other ACEIs, zofenopril is recommended for the management of CVD, including HF, AMI, and LVD, beyond BP control. As per current guidelines, ACEIs are recommended in symptomatic patients with HF with reduced LVEF to reduce the risk of HF hospitalization and in patients after AMI with ST-elevation. Since the effect in reducing the risk of mortality and reinfarction is not specifically associated with a single agent, and is rather described as a class effect, the choice of ACEI therapy can be addressed by the ancillary characteristics of each agent that may confer further benefits to patients.

Fig. 2  

(a) Incidence of the combined end-point (cardiovascular mortality or hospitalization for cardiovascular causes) and hospitalization during the 1-year of treatment with ramipril plus acetylsalicylic acid (n = 351, dashed lines) or zofenopril plus acetylsalicylic acid (n = 365, continuous lines) in the SMILE-4 Study. p values from the log-rank statistics [34, 35]. RRR relative risk reduction, R ramipril, Z zofenopril

(b) Incidence of hospitalization during the 1-year of treatment with ramipril plus acetylsalicylic acid (n = 351, dashed lines) or zofenopril plus acetylsalicylic acid (n = 365, continuous lines) in the SMILE-4 Study.

(c) Incidence of the combined endpoint and hospitalization during the follow-up in patients originally randomized and treated with zofenopril (continuous lines, n = 144) or ramipril (dashed lines, n = 121) in the SMILE-4 Study.

(d) Incidence of the combined endpoint and hospitalization during the follow-up in patients originally randomized and treated with zofenopril (continuous lines, n = 144) or ramipril (dashed lines, n = 121) in the SMILE-4 Study.

Fig. 3  

Occurrence (%) of the different primary endpoints of the study after 6 months of treatment with placebo (n = 177, open bars) or zofenopril (n = 172, full bars) in the patients of the SMILE-3 Study [37]. TT treadmill test, CABG coronary artery bypass graft, PTCA percutaneous transluminal coronary angioplasty. p values refer to the statistical significance of the between-treatment difference
Fig. 4 Cumulative survival without events during 1 year in patients (a) with preserved systolic function (left ventricular ejection fraction > 40%) and (b) with impaired systolic function (left ventricular ejection fraction ≤ 40%) treated with zofenopril (continuous line) or ramipril (dotted line). c Odds ratio and 95% confidence interval for 1-year combined occurrence of cardiovascular mortality or hospitalization for cardiovascular causes according to ranges of left ventricular ejection fraction [38], CI confidence interval, LVEF left ventricular ejection fraction, OR odds ratio, R ramipril, Z zofenopril.

Fig. 5 a Cumulative survival and b cumulative survival without cardiovascular events during 1-year of follow-up in patients treated with placebo (n = 951, dashed lines), other angiotensin-converting enzyme inhibitors (lisinopril or ramipril, n = 871, dotted lines) and zofenopril (n = 1808, continuous line) in the SMILE program. The relative risk reduction versus placebo is indicated. p values from a Cox regression model [39]. Z zofenopril, ACEI angiotensin-converting enzyme inhibitor, RRR relative risk reduction.
ACKNOWLEDGEMENTS

Funding. Sponsorship for the SMILE programme and open access fee were funded by Menarini International Operations Luxembourg S.A. No Rapid Service Fee was received by the journal for the publication of this article. The funding source did not influence or commented on planned methods, protocol, data analysis and the paper. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures. Conflict of interest of Prof Claudio Borghi: consultancy for Boheringer Ingelheim, Menarini International, Sanofi,

Fig. 6 Effect of zofenopril on hydrogen sulfide and nitric oxide bioavailability. By inhibiting myocardial angiotensin-converting enzyme activity, zofenopril reduces the generation of angiotensin II and increases levels of bradykinin. Bradykinin, through stimulation of endothelial B2 receptors, promotes the release of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor, which in turn leads to cardioprotection. On the other hand, zofenopril, by releasing hydrogen sulfide, enhances tissue antioxidant defense, and promotes activation of endothelial nitric oxide synthase, leading to increased levels of nitric oxide. Therefore, angiotensin-converting enzyme inhibition, hydrogen sulfide, and nitric oxide account for zofenopril-mediated cardioprotective effects [40]. ACE angiotensin-converting enzyme, BK bradykinin, EDHF endothelium-derived hyperpolarizing factor, eNOS endothelial nitric oxide synthase, H2S hydrogen sulfide, NO nitric oxide
Amgen, Takeda, Novartis, Ely Lilly and Servier. Stefano Omboni has nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Kalantarinia K, Okusa MD. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diab Rep. 2006;6(1):8–16.

2. Abuissa H, O’Keefe J Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab. 2008;10(12):1157–66.

3. Otto CM. Heartbeat: renin-angiotensin system blockade for prevention of cardiovascular disease. Heart. 2017;103:1305–7.

4. Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9–20.
5. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261–7.

6. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res. 2020;126(10):1456–74.

7. Magellan. Angiotensin modulators: ACE inhibitors and direct renin inhibitors review. Cincinnati: Provider Synergies, LLC; 2012. p. 1–28.

8. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37(7):1757–64.

9. Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017;125(Pt A):57–71.

10. Williams B, Mancia G, Spiering W, et al. Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.

11. Gohlke P, Scholkens BA. ACE inhibitors: pharmacology. In: Unger T, Scholkens BA, editors. Angiotensin. Berlin: Springer; 2004. p. 375–413.

12. Davis R, Coukell A, McTavish D. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Drugs. 1997;54(1):103–16.

13. Heran BS, Wong MMY, Heran IK, Wright J. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;4:CD003823.

14. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–6.

15. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

16. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–81.

17. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2006;47(8):1576–83.

18. Knutti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.

19. Pfeffer M. ACE inhibitors in acute myocardial infarction patient selection and timing. Circulation. 1998;97:2192–4.

20. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202–12.

21. Hansen ML, Gislason GH, Køber L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol. 2008;65(2):217–23.

22. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

23. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Version 2. BMJ. 2013;347:f6008.

24. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol. 2005;16(Suppl 1):S58–63.

25. DeForrest JM, Waldron TL, Krapcho J, et al. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J Cardiovasc Pharmacol. 1989;13:887–94.
26. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. Am J Cardiol. 1991;68:D101–10.

27. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80–5.

28. Borghi C, Bacchelli S, Degli Esposti D, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens. 1999;12:665–72.

29. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E, SMILE Study. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care. 2003;26:1862–8.

30. Borghi C, Cicer AF, Bacchelli S, Degli Esposti D, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol. 2009;23:641–8.

31. Borghi C, Cicer AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag. 2008;4:665–71.

32. Borghi C, Bacchelli S, Degli ED, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am Heart J. 2006;152:470–7.

33. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80–7.

34. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G. SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35(7):416–23.

35. Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Early treatment with zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a 5-year follow-up of patients of the SMILE-4 Study. J Cardiovasc Pharmacol. 2017;69(5):298–304.

36. Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, SMILE-4 Working Party. Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. J Renin Angiotensin Aldosterone Syst. 2016;17(4):1470320316656480.

37. Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE) study—ISCHEMIA study. Am J Heart. 2007;153:445.e7–14.

38. Borghi C, Omboni S, Cicero AF, et al. Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. Open Heart. 2015;2(1):e000195.

39. Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015;2(1):e000220.

40. Donnarumma E, Ali MJ, Rushing AM, et al. Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability. J Am Heart Assoc. 2016;5(7):e003531.

41. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2(4):294–306.

42. Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag. 2011;7:459–71.